This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cold Genesys, Inc.
Drug Names(s): CG7870
Description: CG7870 is a replication-selective oncolytic adenovirus genetically engineered to replicate preferentially in prostate tissue.
Cell Genesys and Novartis
In 2003, Cell Genesys entered into a global alliance with Novartis for the development and commercialization of oncolytic virus therapies. Under the agreement, Cell Genesys has acquired exclusive worldwide rights to the oncolytic virus therapy products and related intellectual property of Genetic Therapy, Inc. (GTI), an affiliate of Novartis, and will receive a signature payment of $28.5 million from Novartis to be dedicated to the further development of several oncolytic virus therapy products from both Cell Genesys and GTI for which Novartis has certain options.
BioSante and Cell Genesys
In June 2009, BioSante Pharmaceuticals and Cell Genesys announced that they entered into a definitive merger agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company. The acquisition was completed in October 2009.
Cold Genesys and BioSante
In November 2010, BioSante announced it sold...See full deal structure in Biomedtracker
Partners: Novartis AG ANI Pharmaceuticals, Inc.
Additional information available to subscribers only: